Back to Search
Start Over
Bone Metastasis Market Forecast 2032: FDA, EMA and PDMA Approvals, Epidemiology, Therapies, Companies by DelveInsight | XGEVA (denosumab), XOFIGO (radium-223 dichloride), Cabozantinib, 9-ING-41, more
- Source :
- M2 Presswire. June 10, 2024
- Publication Year :
- 2024
-
Abstract
- M2 PRESSWIRE-June 10, 2024-: Bone Metastasis Market Forecast 2032: FDA, EMA and PDMA Approvals, Epidemiology, Therapies, Companies by DelveInsight | XGEVA (denosumab), XOFIGO (radium-223 dichloride), Cabozantinib, 9-ING-41, more (C)1994-2024 M2 [...]
- Subjects :
- Daiichi Sankyo Inc. -- Forecasts and trends
Bayer AG -- Forecasts and trends
Pfizer Inc. -- Forecasts and trends
Novartis AG -- Forecasts and trends
Eli Lilly and Co. -- Forecasts and trends
Business -- Research
Denosumab -- Forecasts and trends -- Reports
Metastasis -- Reports -- Forecasts and trends
Brand equity -- Forecasts and trends -- Reports
Drug approval -- Reports -- Forecasts and trends
Epidemiology -- Forecasts and trends -- Reports
Pharmaceutical industry -- Forecasts and trends
Market trend/market analysis
Business
Business, international
Subjects
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- M2 Presswire
- Publication Type :
- News
- Accession number :
- edsgcl.797072335